Compare Nova Ltd (NVMI) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nova Ltd vs Smith & Nephew plc — how do they compare? Nova Ltd trades at $375.01 (market cap $11.99B), while Smith & Nephew plc trades at $27.72 (market cap $11.63B). The key difference: Nova Ltd and Smith & Nephew plc are close in size by market cap, and Smith & Nephew plc pays a 2.85% dividend while Nova Ltd pays none. Which is the better fit depends on your goals.
| NVMI | SNN | |
|---|---|---|
Market Cap | $11.99B | $11.63B |
Sector | Technology | Health |
52-Week High | $605.65 | $38.53 |
52-Week Low | $275.78 | $27.80 |
Enterprise Value | $11.78B | $14.66B |
Dividend Yield | — | 2.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Smith & Nephew (SNN) trades at $27.87, down 3.46% over 24 hours and near its 52-week low. The stock shows a bearish technical trend with mixed sentiment; recent earnings have mostly beaten expectations, but Q2 2026 revenue growth missed and guidance was cut. Fundamentals are solid with revenue rising to $6.16B in 2025 and net income margin improving to 10.08%, though debt levels have increased. The company faces competitive pressures in key markets like U.S. Orthopaedics.
Outlook is cautious: valuation ratios like P/E of 18.96 are reasonable, but analyst consensus is Hold (65%) due to execution risks and CFO departure. Opportunities include innovation in surgical robotics and new product launches, but investors should monitor U.S. market weakness and debt management for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nova Ltd
Nova provides metrology solutions for semiconductor manufacturing. Its systems measure material and process characteristics to help chipmakers control production across advanced nodes and packaging.
Read more on NVMI →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
